

Published in final edited form as:

Genes Immun. 2014 March ; 15(2): 63–71. doi:10.1038/gene.2013.60.

Screen of whole blood responses to flagellin identifies *TLR5* variation associated with outcome in melioidosis

Narisara Chantratita^{1,2}, Sarunporn Tandhavanant^{1,2}, Nicolle D. Myers³, Wirongrong Chierakul^{2,4}, Johanna D. Robertson³, Weera Mahavanakul⁵, Pratap Singhasivanon⁶, Mary J. Emond⁷, Sharon J. Peacock^{1,2,8}, and T. Eoin West^{3,9}

¹Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand ²Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand ³Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, WA, USA ⁴Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand ⁵Department of Medicine, Sappasithiprasong Hospital, Ubon Ratchathani, Thailand ⁶Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand ⁷Department of Biostatistics, University of Washington, Seattle, WA, USA ⁸Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom ⁹International Respiratory and Severe Illness Center, University of Washington, Seattle, WA, USA

Abstract

Melioidosis is a severe infection caused by the flagellated bacterium *Burkholderia pseudomallei*. The nonsense polymorphism *TLR5*_{1174C>T} is associated with improved outcome in Thais with melioidosis. We hypothesized that other *TLR5* variants may modulate the host response and determine outcome in melioidosis. We genotyped 12 *TLR5* variants selected de novo from the HapMap database and examined the association of each with cytokines induced by flagellin stimulation of whole blood from healthy Thai subjects. We found a blunted cytokine response for three related markers that were in linkage disequilibrium with a non-synonymous variant, *TLR5*_{1846T>C}. Carriers of *TLR5*_{1846T>C} had broadly impaired cytokine responses induced by flagellin. *TLR5*_{1846T>C} was associated with protection against death in melioidosis patients (OR 0.62, 95% CI: 0.42-0.93, *p*=0.021). We observed no impairment in *TLR5*_{1846C}-dependent NF-κB activation, however, suggesting an alternative mechanism for the effect. We found that *TLR5*_{1846T>C} was in strong linkage disequilibrium with *TLR5*_{1174C>T}. Many of the blunted cytokine responses observed and the association of *TLR5*_{1846T>C} with survival in melioidosis patients may be attributable to *TLR5*_{1174C>T}, but we could not exclude an independent effect of *TLR5*_{1846T>C}. These data identify novel associations for *TLR5*_{1846T>C}, enhance our understanding of *TLR5* genetic architecture in Thais, and provide future directions of study.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Corresponding author: Narisara Chantratita, Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand Tel: +662 306-9172 Fax: +662 643-5583 narisara@tropmedres.ac

Conflict of Interest The authors declare there is no conflict of interest.

Keywords

meliodosis; TLR5; innate immune response; flagellin; genetic variation

Introduction

A primary host defence mechanism against invading pathogens is the innate immune response which is initiated upon the recognition of pathogen-associated molecular patterns (PAMPs) by pathogen sensors such as toll-like receptors (TLRs).¹ These trans-membrane-receptors use leucine-rich repeat extracellular domains to distinguish the highly conserved structure of pathogens from self-components and mediate the signal via a cytoplasmic receptor homology domain.²

At least ten types of TLRs are present with different density on various cell types in blood and tissue such as macrophage, monocyte, dendritic cells, neutrophils and epithelial cells.^{1, 3} Each TLR recognizes a different group of PAMPs including lipopolysaccharide (LPS) and flagellin from Gram-negative bacteria, lipoteichoic acid from Gram-positive bacteria, bacterial DNA, viral RNA and envelope glycoproteins. The activation of TLRs leads to a massive production of a variety of immune mediators, which are important triggers for inflammatory responses and the connection to adaptive immune response to infections.⁴⁻⁶ TLR5 recognizes flagellin and signals in a MyD88-dependent fashion to activate NF- κ B.^{7, 8} This is in contrast to TLR2 or TLR4 which utilize the additional adaptor molecule TIRAP to recruit MyD88. TLR4 may also signal in a MyD88-independent but TRIF/TRAM-dependent fashion. The final result of these different PAMPs and TLR engagement is the activation of downstream signalling pathways, ultimately resulting in the production of several immune mediators.

TLR5 is the only TLR that responds to flagellin (FliC), a main protein of flagella. Human TLR5 is a type I transmembrane protein with a 642-amino acid leucine-rich extracellular domain, an 18-residue transmembrane domain, and a 198-residue cytoplasmic Toll homology signalling domain.⁹ Several Gram-negative bacteria use flagella to direct movement and facilitate pathogenicity in hosts.¹⁰⁻¹² The flagellins from flagellated bacteria share a common structure which binds to TLR5 and precipitates a MyD88- and NF- κ B-dependent host response.³

Melioidosis is a tropical disease caused by *Burkholderia pseudomallei*, a flagellated Gram-negative soil saprophyte. The disease is endemic mostly in Southeast Asia and Northern Australia.¹³ In northeast Thailand, the overall melioidosis mortality rate is 40%, and reaches 90% in severe infection.^{14, 15} The importance of the innate immune response in control of infection and pathophysiology of lethal melioidosis is documented in several studies. In septicemic melioidosis, TLRs – including TLR5 – and associated molecules are highly expressed.¹⁶ Melioidosis patients who die have elevated plasma levels of pro-inflammatory cytokines IL-12, IL-18, IL-15 and IFN- γ compared to those who survive.¹⁷

We have previously demonstrated that a common nonsense *TLR5* polymorphism that truncates the receptor and abolishes flagellin signalling (*TLR5*_{1174C>T})⁹ is associated with

improved outcome from melioidosis.¹⁸ These data demonstrate the importance of flagellin sensing in melioidosis. Others have shown strong evidence for selection of *TLR5* polymorphisms.¹⁹ We hypothesized that other *TLR5* genetic variants may modulate flagellin signalling and determine outcome from melioidosis independently of *TLR5*_{1174C>T}. To test this hypothesis, we analysed the association of candidate *TLR5* polymorphisms identified de novo from Asian HapMap databases with whole blood responses to flagellin in healthy Thai subjects; examined the association of a tagged coding variant with death from melioidosis; and assayed innate immune activation by the coding variant in transfected cells.

Results

Blood cytokine responses to flagellin are highly correlated

We stimulated blood from 300 healthy Thai subjects with *Salmonella typhimurium* flagellin and measured eight cytokine and chemokine levels 6 h later using a multiplex bead assay (Chantratita *et al.*, submitted for publication).¹⁸ The median age of subjects was 33 years, IQR 24–41. One hundred and twenty seven (42.3%) of the 300 subjects were female. Given non-normal distributions of the cytokine data, we performed log transformations before analyses, resulting in normally distributed residuals. We next examined the data to determine whether any of the eight mediators were highly correlated. We found that IL-6 was highly correlated (pairwise correlation coefficient (r)>0.73) with all mediators (IL-8, TNF- α , IL-10, MCP-1, G-CSF, and IL-1 β) except IL-1ra (Table 1). As a result, we restricted our subsequent analyses to IL-6 and IL-1ra.

TLR5 variants are associated with flagellin-induced cytokine responses in blood

We then tested whether genetic variants in *TLR5* were associated with IL-6 or IL-1ra induced by flagellin stimulation of blood. We identified 12 candidate single nucleotide polymorphisms (SNPs) in *TLR5* selected as described in the methods (rs2072493, rs5744173, rs2096142, rs5744175, rs2241096, rs5744176, rs2241097, rs2353476, rs5744113, rs5744166, rs17163737, rs5744167). We genotyped these variants in the 300 subjects. No assays failed but there was no variation in five variants so these were not considered further. The call rates for the seven remaining variants (rs2072493, rs2096142, rs2241096, rs2241097, rs2353476, rs5744113, rs17163737) were 100% and no variant failed a test for Hardy Weinberg equilibrium. We found that three variants, rs2096142, rs2353476, and rs5744113 were significantly associated with both IL-6 and IL-1ra in additive models (Table 2). We did not adjust for multiple comparisons given the possibility that these variants were not independent. On further investigation, rs2096142, rs2353476, and rs5744113 were in very high linkage disequilibrium with each other ($r^2 = 0.98-1.0$) (Figure 1). We then searched the HapMap Han Chinese in Beijing (HCB) population using the Genome Variation Server (www.gvs.gs.washington.edu) to identify whether the haplotype containing these variants also contained a non-synonymous coding variant that might be functional. We found that the linkage disequilibrium (LD) among the three variants was also very high in this population ($r^2=0.93-1.0$). The only coding variant we identified in LD with the three variants was rs5744174 ($r^2=0.63-0.68$). This non-synonymous coding variant exchanges T for C at position 1846, corresponding to an amino acid change from phenylalanine to leucine at position 616 in the extracellular domain. Recently published

evidence suggests that this variant has been subjected to significant selective pressure in Yorubans.¹⁹ The genomic evolutionary rate profiling (GERP) score, indicating variability across mammals, is -11.2 .²⁰

***TLR5*_{1846T>C} is associated with flagellin-induced cytokine responses in blood**

We then genotyped *TLR5*_{1846T>C} in the 300 Thai subjects (call rate 100%) and found that the LD with our initial three variants was modest ($r^2 \sim 0.5$) (Figure 1). The minor allele frequency of *TLR5*_{1846T>C} was 0.22 and the variant was in Hardy Weinberg equilibrium ($p=0.76$). We tested whether *TLR5*_{1846T>C} was associated with cytokine responses to flagellin using an additive genetic model. We found that the variant was highly associated with lower levels of all mediators except MCP-1 (Table 3 and Figure 2). Monocyte counts, age, and sex are associated with cytokine responses to various bacterial ligands (Chantratita *et al*, unpublished observations). Inclusion of these variables in the model had only modest effects on the point estimates (Supplemental Table 1).

***TLR5*_{1846T>C} is associated with survival from melioidosis**

To determine whether *TLR5*_{1846T>C} was associated with clinical outcome from flagellated infection, we genotyped the variant in a cohort of Thai subjects with melioidosis. Melioidosis is infection caused by the Gram-negative and flagellated soil saprophyte *B. pseudomallei*. Mortality is very high in northeast Thailand. This cohort has been previously described.^{18, 21} Of 600 individuals with melioidosis, the median age was 49, IQR 39-60, and 274 (45.7%) were female. One hundred and forty three (23.8%) died during their hospitalization or were discharged home in extremis for palliative care. DNA was available for genotyping in 588 subjects for whom outcome at hospital discharge was known. The variant was genotyped in 580 individuals (call rate 98.6%) and did not deviate from Hardy Weinberg equilibrium in survivors to hospital discharge ($p=0.89$). We found that *TLR5*_{1846T>C} was significantly associated with protection against in-hospital death in an unadjusted analysis (Table 4). We then tested whether the variant was associated with any pre-existing condition (diabetes, chronic liver disease, renal insufficiency, and steroid use) to identify potential confounders to consider in the analysis but found no associations. In the adjusted model we included factors that were independently associated with death: age, diabetes, renal insufficiency, pneumonia, bacteraemia, and urinary tract infection. This adjusted model confirmed a significantly protective effect of *TLR5*_{1846T>C} against death from melioidosis (odds ratio (OR) 0.62, 95% confidence interval (CI): 0.42-0.93, $p=0.021$). Kaplan-Meier curves demonstrating in-hospital survival for carriers of each genotype were significantly different ($p=0.029$) (Fig. 3).

***TLR5*_{1174C>T} underlies some of the effect of *TLR5*_{1846T>C} on death in melioidosis**

We have previously shown a protective association of *TLR5*_{1174C>T} with death in melioidosis¹⁸. *TLR5*_{1174C>T} is not listed in the HapMap database but we hypothesized that *TLR5*_{1174C>T} might be in LD with *TLR5*_{1846T>C} and potentially explain the association of *TLR5*_{1846T>C} with outcome from melioidosis. We first tested whether *TLR5*_{1846T>C} and *TLR5*_{1174C>T} were in LD in the 300 healthy subjects. We found that $r^2=0.19$ (Figure 1) but $D'=1.0$ and the association between genotypes displayed in a contingency table was

significant ($p=4 \times 10^{-15}$) indicating that the two variants were in LD. No subjects with the major genotype $TLR5_{1846TT}$ carried a $TLR5_{1174T}$ allele but 25% of the $TLR5_{1846TC}$ subjects and 44% of the $TLR5_{1846CC}$ subjects did (Table 5). We next tested the association of $TLR5_{1846T>C}$ with death in melioidosis in the 500 hospitalized subjects who did not carry the rare variant of $TLR5_{1174C>T}$ and found that the effect was no longer significant (adjusted OR 0.87, 95% CI 0.56-1.33, $p=0.51$). However, the power to reject the null hypothesis of no association between death and $TLR5_{1846T>C}$ in this subset that independent of $TLR5_{1174C>T}$ is 50% when the true OR is 0.62. A haplotype analysis of both variants on death confirmed a non-significant effect of $TLR5_{1846C}$ on death in the absence of $TLR5_{1174T}$ and showed a significant protective association of both $TLR5_{1174T}$ and $TLR5_{1846C}$ with death (Table 6). The frequency of the haplotype containing $TLR5_{1846C}$ but not $TLR5_{1174T}$ was too low to test the association with death. Thus, we concluded that, for these two non-synonymous $TLR5$ variants in LD, there is strong evidence for an effect on death of both variants together while the effect of $TLR5_{1846T>C}$ alone is indeterminate.

The association of $TLR5_{1846T>C}$ on flagellin-induced cytokine release is partly attributable to $TLR5_{1174C>T}$

We have previously shown that $TLR5_{1174C>T}$ significantly reduces all eight cytokine responses induced by stimulation of blood by flagellin.¹⁸ This work extended original studies by Hawn *et al* who also demonstrated the lack of flagellin-induced NF- κ B activation by this variant, independent of $TLR5_{1846T>C}$.⁹ To investigate whether $TLR5_{1846T>C}$ was associated with reduced cytokine release in whole blood independent of $TLR5_{1174C>T}$ we repeated our analysis of the effect of $TLR5_{1846T>C}$ on cytokine release in response to flagellin excluding carriers of the $TLR5_{1174C>T}$ variant allele. In comparison to all subjects, we found that the effect of $TLR5_{1846T>C}$ on lowered cytokine response in this subset was attenuated for all cytokines (excluding MCP-1). The relative reduction in effect of $TLR5_{1846T>C}$ ranged from 43% for IL-6 to 16% for IL-1ra. The point estimates were uniformly negative and the p value for a joint test of all eight differences, accounting for correlation among the cytokines, was 0.08. The associations between $TLR5_{1846T>C}$ and reduced cytokine response remained significant individually only for G-CSF and IL-1 β (Table 7). These data suggest that the association of $TLR5_{1846T>C}$ with impaired cytokine release may be partly attributable to $TLR5_{1174C>T}$.

$TLR5_{1846T>C}$ is not dysfunctional in NF- κ B signalling

To further investigate whether $TLR5_{1846T>C}$ was independently associated with altered flagellin signalling we performed site directed mutagenesis on a previously described $TLR5$ construct⁹ to construct a mutant $TLR5$ plasmid corresponding to $TLR5_{1846T>C}$. Sequence verification confirmed the base change at position 1846 and the absence of any other known non-synonymous variation in the full $TLR5$ coding sequence in the plasmid (Figure 4A). We transfected HEK 293 cells with $TLR5_{1846T}$ and $TLR5_{1846C}$ and assayed NF- κ B activation by luciferase reporter assay following stimulation with 50, 100 and 200 ng/mL flagellin. The cells transfected with $TLR5_{1846C}$ showed no difference in NF- κ B activation compared to $TLR5_{1846T}$ -transfected cells (Figure 4B). These data indicated that in this construct $TLR5_{1846T>C}$ does not impair flagellin-driven innate immune activation via NF- κ B.

Differential linkage disequilibrium of variants with $TLR5_{1846T>C}$ across populations

In light of the evidence in favour of selection for $TLR5_{1846T>C}$ in Yorubans¹⁹, but our inability to conclusively determine a clinical effect of $TLR5_{1846T>C}$ independent of $TLR5_{1174C>T}$ in Thais, we hypothesized that there may be significant population-level differences in LD structure in $TLR5$. We examined the distribution of variants in LD with $TLR5_{1846T>C}$ in three populations (Yorubans, Utah residents with ancestry from northern and western Europe, and Han Chinese) sequenced by the 1000 Genomes Project.²² The degree of LD between $TLR5_{1846T>C}$ and $TLR5_{1174C>T}$ was comparable in the three populations (r^2 : 0.26, 0.12, 0.16; D' : 1.0, 1.0, 1.0, respectively) raising the possibility that positive selection for $TLR5_{1846T>C}$ in Yorubans may be related to $TLR5_{1174C>T}$. However, there were marked inter-population differences in the degree of LD between other variants and $TLR5_{1846T>C}$ (Figure 5). Overall, the Yoruban population differed the most from the other two populations. Moreover, the LD structure of the entire $TLR5$ gene differed greatly across the three populations (Supplemental Figures 1 and 2). Thus, additional variation in $TLR5$ may confound differential evolutionary and clinical associations.

Discussion

The results of our study identify a tagged $TLR5$ non-synonymous coding variant, $TLR5_{1846T>C}$, that is associated with reduced cytokine responses to flagellin in human blood and further show that it is associated with protection against death in melioidosis. In vitro studies demonstrate that the variant does not alter NF- κ B activation induced by flagellin, however, and the cytokine and clinical effects observed are in large part driven by previously described hypofunctional variant that is in LD with $TLR5_{1846T>C}$, $TLR5_{1174C>T}$. Collectively, these data identify new biological and clinical associations for $TLR5_{1846T>C}$, advance our understanding of genetic variation in $TLR5$ in Thais, and confirm the relevance of $TLR5$ variation in determining outcome in melioidosis.

Although it is known that TLRs are important in regulating innate immune responses³, only a few reports have demonstrated the clinical significance of $TLR5$ polymorphisms in bacterial infections. Studies demonstrating an association have mostly been restricted to a functional nonsense polymorphism $TLR5_{1174C>T}$.^{9, 18} Accordingly, we searched for additional genetic variation in $TLR5$ that might have functional effects and clinical relevance in melioidosis. Knowledge of innate immune genetic variation in Thais is limited, necessitating that we choose candidate variants based on publically available data from other populations. Our data therefore provide the first published data on frequency and LD patterns of $TLR5$ genetic variation in Thais.

Our main finding in this work is that $TLR5_{1846T>C}$ (F616L) is associated with broadly reduced cytokine responses to flagellin and protection against death in melioidosis. Other investigators have reported associations of $TLR5_{1846T>C}$ with immune responses and clinical disease. The variant is associated with earlier spontaneous Hepatitis B virus e antigen (HBeAg) seroconversion (disappearance of serum HBeAg and the presence of anti-HBeAg for >6 months) and higher levels of IFN- γ production in Taiwanese patients with chronic Hepatitis B infection.²³ $TLR5_{1846T>C}$ is also associated with gastric cancer and interacts with *Helicobacter pylori* infection in a cohort of Chinese subjects.²⁴ The variant is also

associated with higher measles-specific IFN- γ responses.²⁵ The associations with viral infections raise the question of a role for this variant that is unrelated to flagellin sensing.

A key question that arises from our data is whether *TLR5*_{1846T>C} has a biological or clinical effect that is independent of the nonsense polymorphism with which it is in LD, *TLR5*_{1174C>T}. Notably, we did not observe any impairment in NF- κ B activation upon stimulation of cells expressing *TLR5*_{1846C} alone. This observation confirms the results of other investigators.^{9, 26} In contrast, a more recent study reports a *TLR5*_{1846C}-dependent decrement in NF- κ B activation.¹⁹ Although in the extracellular domain, amino acid 616 is outside the known flagellin binding sites^{27, 28} and variation at this site is predicted to be benign by Polyphen2.²⁹ A potential explanation for observed differences between investigators is the source of the *TLR5* plasmids studied in these experiments. We show marked differences in LD structure in *TLR5* across populations and potentially confounding effects of additional *TLR5* variation in plasmids from subjects of different ancestries. In addition, a plasmid generated by mutagenesis of a single locus may yield different functional effects than DNA derived from a carrier of the desired genotype (and accompanying haplotype). We largely attribute our associations of *TLR5*_{1846T>C} with blunted whole blood cytokine responses and improved clinical outcome to *TLR5*_{1174C>T}. However, some of the effects of *TLR5*_{1846T>C} on G-CSF and IL-1 β release in whole blood persisted despite excluding carriers of *TLR5*_{1174C>T} from our analysis. Our study of the association of *TLR5*_{1846T>C} with death from melioidosis in the absence of *TLR5*_{1174C>T} was underpowered and therefore inconclusive. Moreover, in contrast to their observations for *TLR5*_{1846T>C}, Wu *et al* did not find that *TLR5*_{1174C>T} was associated with age of HBeAg seroconversion.²³ Thus, we cannot exclude the possibility that *TLR5*_{1846T>C} has an immunomodulatory effect independent of *TLR5*_{1174C>T}. Further work to elucidate the functional effects of *TLR5* variants in different populations is needed.

Our study has several limitations. We cannot exclude that there may be additional interactive effects of unmeasured *TLR5* variation that could alter our results. We analysed a relatively restricted number of *TLR5* variants in our subjects but we anticipate analysing this region more intensively in the future. Although population stratification may confound any genetic analysis, we have previously shown that we did not detect significant evidence of this in our Sappasithprasong Hospital cohort.¹⁸

In conclusion, we demonstrate novel biological and clinical associations for *TLR5*_{1846T>C}, present new information about *TLR5* genetic structure in Thais, and underscore the importance of understanding the role of TLR5 in modulating outcome in melioidosis. Further work is needed to dissect the relative biological contributions of differential *TLR5* variation in diverse populations.

Materials and methods

Human subjects

Immuno-assay studies: Three-hundred healthy Thai subjects donating blood at the blood donation centre at Sappasithprasong Hospital in 2010 were recruited for participation as previously described.¹⁸ Subjects were included if their stated age was between 18 and 60

years, and did not report any history of immunodeficiency or inflammatory conditions, chronic diseases, pregnancy in the past six months, anti-inflammatory medication use in the past week, antibiotic use in the past month, vaccination in the past six months, heavy exercise or alcohol consumption in the past 24 h, or smoking in the past month. Those who met enrollment criteria gave written informed consent to participate and provided a post-donation blood sample.

Melioidosis cohort: The study cohort has been previously described.¹⁸ Clinical data and blood were obtained from 588 patients with melioidosis admitted to Sappasithiprasong Hospital, Ubon Ratchathani, Thailand from 1999 to 2005. A study team screening patients with clinical signs of infection cultured blood, urine and other relevant samples (for example, abscess aspirates) for *B. pseudomallei*. Inclusion into the melioidosis cohort required a positive culture for *B. pseudomallei* from a sample collected by the study team or independently by hospital clinicians. For the analyses of genotype with death from melioidosis, deaths were defined as those individuals who died during their hospitalization or were discharged home in extremis for palliative care. Consent for enrollment into clinical studies of melioidosis was obtained from subjects or their representatives at the time of recruitment.

The Ethical Review Committee for Research in Human Subjects, Ministry of Public Health, Thailand; the Ethical Review Committee for Research in Human Subjects, Sappasithiprasong Hospital, Ubon Ratchathani, Thailand; the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; and the University of Washington Human Subjects Division Institutional Review Board approved the studies.

Immuno-assays

Three hundred and eighty microliters of fresh whole blood in citrate mixed 1:1 with RPMI media was added to pre-prepared plates containing 20 μ L of various stimulants. For this study, the stimulants analysed were *S. typhimurium* flagellin at a final concentration of 500 ng/mL and *Escherichia coli* LPS 10 ng/mL (List Biologicals). Plates were incubated at 37 °C on a shaking incubator under 5% CO₂ for 6 h before being spun down and plasma removed and frozen at -80 °C. IL-6, IL-8, TNF- α , IL-10, MCP-1, IL-1ra, G-CSF, and IL-1 β were later assayed in duplicate on a multiplex bead system (Luminex, Austin, TX) using reagents from R&D Systems (Minneapolis, MN). If either (or both) duplicate(s) was less than the lower limit of detection of the assay, it was assigned the lowest detectable value of any of the 300 subjects' duplicate raw results for that cytokine induced by the same stimulant, a form of data imputation. The amended duplicate values were then averaged to provide a final cytokine concentration. A complete blood count with differential was performed in the hospital clinical laboratory for each subject at the time of phlebotomy.

Genotyping

DNA was extracted from whole blood of healthy donors using the QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany) and from whole blood of patients with melioidosis using Nucleon BACC3 kits (GE Healthcare, Buckinghamshire, UK). SNP selection of non-synonymous coding variants was performed by searching the HapMap project database

(<http://hapmap.ncbi.nlm.nih.gov>) and based on functional prediction using a FastSNP analysis (<http://fastsnp.ibms.sinica.edu.tw>).³⁰ Tag SNPs were selected from the Han Chinese in Beijing and Japanese in Tokyo populations in the HapMap database for variants with a minor allele frequency at least 2% using the HapMap tag-SNP picker option. *TLR5*_{1174C>T} (rs5744168) was not listed in the HapMap database for these populations. Genotyping was performed using Fluidigm SNPtype assays on a Biomark microfluidics real time PCR system or using ABI TaqMan assays on an ABI Prism 7900 (Carlsbad, CA).

Cloning and site-directed mutagenesis

A T to C mutation in *TLR5* at position 1846 was constructed with a QuikChange II site-directed mutagenesis kit (Stratagene, CA). The coding region of *TLR5* was amplified from 7.5 ng plasmid template *TLR5*-RNF-V5-pEF6 which contained full-length human *TLR5* coding region cloned into the pEF6/V5-His TOPO expression vector (Invitrogen, CA)⁹ in a 25 μ L reaction volume. *TLR5*-RNF-V5-pEF6 was a gift from Thomas R. Hawn, University of Washington, Seattle, WA. Mutagenic primers were designed from *TLR5* mRNA sequence (Gen Bank accession no. AB060695.1) using software from <http://labtools.stratagene.com/QC>. The forward primer was modified to replace T with C at the position 1846 corresponding to rs5744174. The sequences of primers from 5' to 3' were as follows: F-GTGTACCCTGACTCGCTCTCTGGGGTTTCCC and R-GGGAAACCCAGAGAGCGAGTCAGGGTACAC. The PCR reaction mixture was performed with *PfuUltra* high-fidelity (HF) DNA polymerase according to the protocol described by manufacturer and the conditions were as follows: initial denaturation at 95 °C for 1min; 12 cycles of denaturation at 95 °C for 1 min, annealing at 60 °C for 1 min, and extension at 68 °C for 15 min; and the reaction was cooled to 4 °C for 1 min. The parental methylated and hemimethylated DNA remaining in amplification product was digested with 1 μ L of 10 U/ μ L *Dpn* I restriction enzyme at 37 °C for 1 h. The mutant *TLR5* plasmid (containing 5,840 bp plasmid and 2,574 bp *TLR5* insert) was transformed into *E. coli* DH5 α . The clones with mutant constructs were selected from plates containing 100 μ g/mL ampicillin. Colonies containing the desired plasmids were analysed by PCR using T7 promoter forward and BGH reverse primers flanking the *TLR5* mutant alleles from 5' to 3' as follows: F- TAATACGACTCACTATAGGG and R- TAGAAGGCACAGTCGAGG. The plasmids were extracted from *E. coli* using a QIAprep spin miniprep kit (Qiagen) and DNA sequence was verified by DNA sequencing (Macrogen, Korea). The sequence of the mutant clone was analysed and aligned with the sequence of *TLR5*-RNF-V5-pEF6 wild type using Seqman software (Laser gene) version 8 (DNASTAR Inc., WI, USA) and MEGA version 5.³¹ The plasmid from the selected clone was extracted for HEK 293 cell transfection experiment using Endo free plasmid purification (Qiagen).

Transfections

HEK 293 cells (CRL-1573, ATCC) were transfected and stimulated as described previously with some modifications.^{9, 18} HEK 293 cells were cultured in complete Dulbecco's Modification of Eagle's Medium (DMEM) without sodium pyruvate and were supplemented with L-glutamine, 4.5 g/L glucose (Mediatech Cellgro, VA) and 10% fetal bovine serum (FBS) (Hyclone, Illinois). Transfection was performed with 5×10^4 cells/well HEK 293 cells in a 96-well plate with 100 μ L transfection reagent containing 0.5 μ L Polyfect reagent

(Qiagen, Hilden, Germany), 10 ng pNiFty-Luc firefly luciferase reporter (Invivogen, CA), 1 ng pRL-TK Renilla luciferase control reporter (Promega, WI) and 40 ng of plasmid (*TLR5*_{1846T} wild type or *TLR5*_{1846C} variant or pEF6 control). Before transfection, the plasmids were prepared in DMEM without FBS and mixed with Polyfect reagent by vortexing for 10 s, incubated at room temperature for 10 min and the volume adjusted to 100 μ L with complete DMEM medium.

Transfected HEK 293 cells were stimulated with 100 μ L of 100, 200 and 400 ng/mL of ultra purified flagellin from *S. typhimurium* (Invivogen) to obtain final concentration 50, 100 and 200 ng/mL. The plate was centrifuged at 200 $\times g$ at room temperature for 3 min and incubated at 37 $^{\circ}$ C with 5% CO₂ for 24 h. The cells were washed 2 times with 100 μ L Dulbecco's Phosphate-Buffered Saline (DPBS) without Ca²⁺ or Mg²⁺ (Mediatech Cellgro, VA), lysed with 40 μ L passive lysis buffer with shaking at room temperature for 15 min. Twenty microliters of lysate was measured for luminescence using the Dual-Luciferase Reporter Assay (Promega) on a GloMax Multi Detection System (Promega). The experiment was performed in triplicate.

Statistics

As immune-assay cytokine concentrations were often non-normally distributed, they were log₁₀ transformed to obtain normally distributed residuals for estimation of pairwise correlations and for estimation of genotype association with cytokine levels. Associations between genotype as a predictor of cytokine concentration were performed using linear regression, coding the genotype to reflect dominant, recessive, or additive genetic models. This is equivalent to testing for differences in mean cytokine levels between genotype groups (and allows adjustment for confounding). Where indicated, this model was adjusted for age, sex, and monocyte count. Associations between genotype or haplotype and death were tested using logistic regression, assuming an additive genetic model. This model was adjusted for age, diabetes, renal insufficiency, pneumonia, bacteraemia, and urinary tract infection. Survival analyses were performed with a test for trend across genotypes. Statistics were performed with R (version 2.15.2; GNU project [<http://www.r-project.org>]) or with Stata 11.2 (College Station, TX), incorporating the functions pwld for test for linkage disequilibrium, genhw to test for deviation from Hardy-Weinberg equilibrium using the exact test, and haplogit for haplotype analyses. Golden Helix SNP & Variation Suite software (Bozeman, MT) was used to calculate linkage disequilibrium and generate maps. A two-sided *p* value ≤ 0.05 was considered significant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors acknowledge the support of the staff and patients at Sappasithiprasong Hospital and Mahidol-Oxford Tropical Medicine Research Unit; DNA extraction by Premjit Amornchai, Aunchalee Thanwisai, and Malinee Oyuchua; assistance generating immuno-assays from Mark Wurfel; and generation of LD maps by Johanna Robertson.

This work was supported by the Wellcome Trust [087769/Z/08/Z to N.C.]; the NIHR Cambridge Biomedical Research Centre [to S.J.P.]; National Institutes of Health awards [K08HL094759 and R01HL113382 to T.E.W.] and by the Doris Duke Charitable Foundation [to T.E.W.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Takeda K, Kaisho T, Akira S. Toll-like receptors. *Annu Rev Immunol.* 2003; 21:335–76. [PubMed: 12524386]
2. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. *Nat Rev Immunol.* 2007; 7(5):353–64. [PubMed: 17457343]
3. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. *Clin Microbiol Rev.* 2009; 22(2):240–73. [PubMed: 19366914]
4. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. *Science.* 2008; 320(5874):379–81. [PubMed: 18420935]
5. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. *Cell.* 2007; 130(6):1071–82. [PubMed: 17889651]
6. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature.* 2009; 458(7242):1191–5. [PubMed: 19252480]
7. Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. *Nature.* 2011; 477(7366):596–600. [PubMed: 21918512]
8. Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, et al. Structural basis of TLR5-flagellin recognition and signaling. *Science.* 2012; 335(6070):859–64. [PubMed: 22344444]
9. Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ, et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. *J Exp Med.* 2003; 198(10):1563–72. [PubMed: 14623910]
10. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. *Nature.* 2001; 410(6832):1099–103. [PubMed: 11323673]
11. Andersen-Nissen E, Smith KD, Strobe KL, Barrett SL, Cookson BT, Logan SM, et al. Evasion of Toll-like receptor 5 by flagellated bacteria. *Proc Natl Acad Sci U S A.* 2005; 102(26):9247–52. [PubMed: 15956202]
12. Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. *Nat Immunol.* 2003; 4(12):1247–53. [PubMed: 14625549]
13. Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. *N Engl J Med.* 2012; 367(11):1035–44. [PubMed: 22970946]
14. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insights into the pathogenicity of *Burkholderia pseudomallei*. *Nat Rev Microbiol.* 2006; 4(4):272–82. [PubMed: 16541135]
15. Limmathurotsakul D, Peacock SJ. Melioidosis: a clinical overview. *Br Med Bull.* 2011; 99:125–39. [PubMed: 21558159]
16. Wiersinga WJ, Wieland CW, Dessing MC, Chantratita N, Cheng AC, Limmathurotsakul D, et al. Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by *Burkholderia pseudomallei* (Melioidosis). *PLoS Med.* 2007; 4(7):e248. [PubMed: 17676990]
17. Friedland JS, Suputtamongkol Y, Remick DG, Chaowagul W, Strieter RM, Kunkel SL, et al. Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized *Pseudomonas pseudomallei* infection. *Infect Immun.* 1992; 60(6):2402–8. [PubMed: 1375198]

18. West TE, Chantratita N, Chierakul W, Limmathurotsakul D, Wuthiekanun V, Myers ND, et al. Impaired TLR5 Functionality Is Associated with Survival in Melioidosis. *J Immunol.* 2013; 190(7):3373–9. [PubMed: 23447684]
19. Grossman SR, Andersen KG, Shlyakhter I, Tabrizi S, Winnicki S, Yen A, et al. Identifying recent adaptations in large-scale genomic data. *Cell.* 2013; 152(4):703–13. [PubMed: 23415221]
20. Cooper GM, Stone EA, Asimenos G, Green ED, Batzoglou S, Sidow A. Distribution and intensity of constraint in mammalian genomic sequence. *Genome Res.* 2005; 15(7):901–13. [PubMed: 15965027]
21. West TE, Chierakul W, Chantratita N, Limmathurotsakul D, Wuthiekanun V, Emond MJ, et al. Toll-like receptor 4 region genetic variants are associated with susceptibility to melioidosis. *Genes Immun.* 2012; 13(1):38–46. [PubMed: 21776015]
22. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature.* 2012; 491(7422):56–65. [PubMed: 23128226]
23. Wu JF, Chen CH, Ni YH, Lin YT, Chen HL, Hsu HY, et al. Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in Taiwan. *J Infect Dis.* 2012; 206(5):662–8. [PubMed: 22740716]
24. Zeng HM, Pan KF, Zhang Y, Zhang L, Ma JL, Zhou T, et al. Genetic variants of toll-like receptor 2 and 5, helicobacter pylori infection, and risk of gastric cancer and its precursors in a chinese population. *Cancer Epidemiol Biomarkers Prev.* 2011; 20(12):2594–602. [PubMed: 21994405]
25. Dhiman N, Ovsyannikova IG, Vierkant RA, Ryan JE, Pankratz VS, Jacobson RM, et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. *Vaccine.* 2008; 26(14):1731–6. [PubMed: 18325643]
26. Merx S, Zimmer W, Neumaier M, Ahmad-Nejad P. Characterization and functional investigation of single nucleotide polymorphisms (SNPs) in the human TLR5 gene. *Hum Mutat.* 2006; 27(3): 293. [PubMed: 16470719]
27. Mizel SB, West AP, Hantgan RR. Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin. *J Biol Chem.* 2003; 278(26):23624–9. [PubMed: 12711596]
28. Andersen-Nissen E, Smith KD, Bonneau R, Strong RK, Aderem A. A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin. *J Exp Med.* 2007; 204(2):393–403. [PubMed: 17283206]
29. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nat Methods.* 2010; 7(4):248–9. [PubMed: 20354512]
30. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. *Nucleic Acids Res.* 2006; 34(Web Server issue):W635–41. [PubMed: 16845089]
31. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol.* 2011; 28(10):2731–9. [PubMed: 21546353]




Figure 1. *TLR5* variant linkage disequilibrium map in healthy Thai subjects
 r^2 values for seven screening *TLR5* variants outlined by blue boxes, *TLR5*_{1846T>C} (rs5744174) and *TLR5*_{1174C>T} (rs5744168) in 300 healthy subjects.




Figure 2. Cytokine responses induced by flagellin are lower in carriers of the *TLR5*_{1846T>C} Whole blood from 300 healthy subjects was incubated with media alone, flagellin 500 ng/mL or *E. coli* LPS 10 ng/mL for 6 h at 37 °C. Plasma cytokines were assayed by multiplex bead assay. Boxes show the median and interquartile range; whiskers show upper and lower adjacent values. Outside values are not shown for clarity. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$ by linear regression for an additive genetic model.





Figure 3. Survival from melioidosis is enhanced for carriers of *TLR5*_{1846T>C}
Kaplan–Meier in-hospital survival curves are plotted for melioidosis subjects, grouped by genotype. Curves are significantly different by the test for trend ($p = 0.029$).

A



B




Figure 4. *TLR5*_{1846T>C} does not impair flagellin-induced NF- κ B activation

(A) Sequence chromatogram indicating a single T to C substitution in *TLR5* at 1846 in the mutant plasmid (lower picture) compared to the wild type plasmid (upper picture).

Alteration of corresponding amino acid from phenylalanine to leucine at position 616 is shown.

(B) HEK 293 cells were transfected with 40 ng of pEF6 plasmid control, *TLR5*_{1846T} or *TLR5*_{1846C}. Cells were stimulated with 50, 100, or 200 ng/mL of purified flagellin from *S. typhimurium* and NF- κ B activity was quantified by dual luciferase assay.




Figure 5. Population differences in $TLR5_{1846T>C}$ LD structure

(A) r^2 and (B) D' was calculated for $TLR5_{1846T>C}$ and each of 733 polymorphic sites in the $TLR5$ gene region from Phase 1 1000 Genomes data for Utah residents with ancestry from northern and western Europe (CEU), Yoruban (YRI) and Han Chinese (CHB) populations. The pairwise difference in these LD measures for each population pair is shown for the 233 variants for which at least one difference was non-zero. The red line indicates the position of $TLR5_{1846T>C}$ and the magenta line indicates the position of $TLR5_{1174C>T}$ on chromosome 1. A map of $TLR5$ is shown for reference.

Table 1
Correlation between blood cytokines induced by flagellin

Inter-cytokine correlation ¹								
	IL-6	IL-8	TNF- α	IL-10	MCP-1	IL-1ra	G-CSF	IL-1 β
IL-6	1.00							
IL-8	0.87	1.00						
TNF-α	0.94	0.88	1.00					
IL-10	0.86	0.75	0.79	1.00				
MCP-1	0.73	0.65	0.63	0.70	1.00			
IL-1ra	0.56	0.41	0.51	0.55	0.58	1.00		
G-CSF	0.87	0.82	0.85	0.82	0.61	0.46	1.00	
IL-1β	0.83	0.87	0.84	0.71	0.66	0.50	0.75	1.00

¹ Pairwise correlation coefficient (r) between log-transformed cytokines induced by stimulation of whole blood from 300 healthy subjects with 500 ng/mL flagellin.

Table 2
Association of *TLR5* variants with blood cytokine response to flagellin

Variant	Minor allele frequency	Cytokine					
		IL-6			IL-1ra		
		<i>P</i> values ¹					
		Dominant	Recessive	Additive	Dominant	Recessive	Additive
rs2072493	0.26	0.202	0.72	0.246	0.468	0.957	0.579
rs2096142	0.23	0.027	0.039	0.010	0.261	0.002	0.032
rs2241096	0.25	0.127	0.139	0.070	0.043	0.128	0.027
rs2241097	0.04	0.324	0.259	0.245	0.051	0.745	0.058
rs2353476	0.23	0.027	0.039	0.010	0.261	0.002	0.032
rs5744113	0.23	0.023	0.058	0.011	0.253	0.005	0.042
rs17163737	0.21	0.017	0.619	0.051	0.050	0.509	0.052

¹*P* values determined by linear regression of association of each variant with log transformed cytokine level induced by stimulation of whole blood from 300 healthy subjects with 500 ng/mL flagellin.

Table 3
Association of *TLR5*_{1846T>C} with blood cytokine release induced by flagellin

Cytokine	Coefficient ^I	95% CI	P
IL-6	-0.168	-0.280 – -0.056	0.003
IL-8	-0.180	-0.277 – -0.084	2.8 × 10 ⁻⁴
TNF-α	-0.153	-0.252 – -0.054	0.003
IL-10	-0.151	-0.273 – -0.029	0.015
MCP-1	-0.048	-0.114 – 0.018	0.155
IL-1ra	-0.038	-0.072 – -0.004	0.028
G-CSF	-0.253	-0.400 – -0.107	7.7 × 10 ⁻⁴
IL-1β	-0.169	-0.263 – -0.076	4.1 × 10 ⁻⁴

^ILinear regression coefficient for *TLR5*_{1846T>C} on log transformed cytokine levels induced by stimulation of whole blood from 300 healthy subjects with 500 ng/mL flagellin.

Table 4
Unadjusted association of *TLR5*_{1846T>C} with death in subjects with melioidosis

Genotype	Death		OR	95% CI	<i>p</i> ¹
	No	Yes			
TT	263 (73.5%)	95 (26.5%)			
TC	156 (79.6%)	40 (20.4%)	0.64	0.44-0.91	0.014
CC	24 (92.3%)	2 (7.7%)			

¹Additive model *P* value calculated by logistic regression.

Table 5
Relationship between *TLR5*_{1846T>C} and *TLR5*_{1174C>T}

Variant	Genotype ^I	<i>TLR5</i> _{1174C>T}		
		CC	CT	TT
<i>TLR5</i> _{1846T>C}	TT	183 (100%)	0 (0.0%)	0 (0.0%)
	TC	77 (76.2%)	24 (24.8%)	0 (0.0%)
	CC	9 (56.3%)	7 (43.8%)	0 (0.0%)

^IGenotypes determined in 300 healthy subjects.

Table 6
Association of *TLR5* haplotype with death in melioidosis patients

Haplotype ^I	<i>TLR5</i> _{1174C>T} _ <i>TLR5</i> _{1846T>C}			
	00	01	10	11
Frequency	0.77	0.15	0.001	0.08
OR (95% CI)		0.85 (0.57-1.25)	-	0.25 (0.11-0.57)
<i>P</i> value		0.41	-	0.001

^I 0 indicates common allele and 1 indicates rare allele at each of the two *TLR5* loci. The major haplotype (00) is set as the reference; the 10 haplotype is not analyzed due to its low frequency. Associations are determined by logistic regression, adjusting for age, diabetes, renal insufficiency, pneumonia, bacteraemia, and urinary tract infection.

Table 7
Association of $TLR5_{1846T>C}$ with blood cytokine release induced by flagellin independent of $TLR5_{1174C>T}$

Cytokine	Coefficient ^I	95% CI	P
IL-6	-0.095	-0.226 – 0.035	0.152
IL-8	-0.110	-0.223 – 0.003	0.057
TNF-α	-0.080	-0.196 – 0.036	0.174
IL-10	-0.095	-0.237 – 0.047	0.188
MCP-1	-0.022	-0.100 – 0.056	0.575
IL-1ra	-0.032	-0.072 – 0.007	0.115
G-CSF	-0.205	-0.381 – -0.030	0.022
IL-1β	-0.120	-0.229 – -0.010	0.032

^ILinear regression coefficient for $TLR5_{1846T>C}$ on log transformed cytokine levels induced by stimulation of whole blood from 269 healthy $TLR5_{1174CC}$ subjects with 500 ng/mL flagellin.